Details of the Drug Pharmacogenomic Perturbation Atlas

Naphazoline Drug Info

Antan; Clearine; Nafazolin; Nafazolina; Nafazoline; Naphazolinum; Naphthizine; Opcon; Nafazolina [DCIT]; Nafazoline [Spanish]; Naphazoline Monohydrochloride; Naphazolinum [Latin]; Enamine_000333; Alpha-Naphthylmethyl imidazoline; Ciba 2020/R; Nafazolin (TN); Naphazoline (INN); Naphazoline [INN:BAN]; Naphazolinum [INN-Latin]; AK-968/41090774; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(Naphthyl-(1')-methyl)imidazolin [German]; 2-(alpha-Naphthylmethyl)-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID

4436

ChEBI ID

CHEMBL761

CAS Number

CAS 835-31-4

TTD Drug ID

D0O6IZ

ACDINA Drug ID

D01273

General Information of Drug (ID: DMJFZDL)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Ubiquinone and other terpenoid-quinone biosynthesis	1.76	2.33e-1	9/11 (81.82%)	NQO1
Chemokine signaling pathway	1.64	4.56e-1	163/192 (84.9%)	CXCL14;CCL19;CXCL9;...
Systemic lupus erythematosus	1.57	5.09e-1	45/135 (33.33%)	C1S;ACTN4;SNRPD1;...
Fatty acid degradation	1.57	4.03e-1	40/43 (93.02%)	ACSL1;ACAA2;ACAT1;...
Cell cycle	1.55	3.70e-1	110/124 (88.71%)	PCNA;CDC25B;CDC20;...
Pentose phosphate pathway	1.53	3.94e-1	25/30 (83.33%)	PFKL;TKT;RGN;...
Base excision repair	1.51	3.83e-1	29/33 (87.88%)	PCNA;PARP2;NEIL3;...
MicroRNAs in cancer	1.51	3.48e-1	146/310 (47.1%)	TIMP3;CASP3;KRAS;...
DNA replication	1.51	3.09e-1	34/36 (94.44%)	PCNA;FEN1;MCM4;...
Apelin signaling pathway	1.47	3.84e-1	117/137 (85.4%)	KRAS;MEF2C;AGTR1;...
Fatty acid elongation	1.47	3.57e-1	19/27 (70.37%)	ACAA2;PPT1;ECHS1;...
Acute myeloid leukemia	1.46	3.53e-1	66/67 (98.51%)	KRAS;ITGAM;CD14;...
Viral carcinogenesis	1.43	4.00e-1	149/203 (73.4%)	CASP3;KRAS;CDC20;...
Neutrophil extracellular trap formation	1.42	3.97e-1	101/189 (53.44%)	TLR4;ITGAM;CYBB;...
Lysine degradation	1.42	3.91e-1	51/63 (80.95%)	BBOX1;DLD;ACAT1;...
Phagosome	1.40	4.11e-1	118/152 (77.63%)	TLR4;THBS1;ITGAM;...
Complement and coagulation cascades	1.40	3.93e-1	76/85 (89.41%)	C1S;ITGAM;F12;...
Mismatch repair	1.39	4.02e-1	22/23 (95.65%)	PCNA;RFC3;MSH2;...
Staphylococcus aureus infection	1.37	4.16e-1	72/95 (75.79%)	C1S;ITGAM;C1QA;...
Proximal tubule bicarbonate reclamation	1.35	4.58e-1	21/23 (91.3%)	SLC4A4;ATP1A2;CA2;...
Thyroid cancer	1.35	4.45e-1	36/37 (97.3%)	KRAS;GADD45B;LEF1;...
PD-L1 expression and PD-1 checkpoint pathway in cancer	1.33	4.78e-1	79/89 (88.76%)	TLR4;KRAS;PRKCQ;...
Yersinia infection	1.32	4.97e-1	120/137 (87.59%)	ITGA4;TLR4;GNAQ;...
alpha-Linolenic acid metabolism	1.31	5.02e-1	17/25 (68%)	PLAAT3;PLA2G2D;FADS2;...
One carbon pool by folate	1.31	4.89e-1	15/20 (75%)	TYMS;DHFR;MTHFD2L;...
Salmonella infection	1.30	4.92e-1	198/249 (79.52%)	TLR4;CASP3;S100A10;...
Leishmaniasis	1.29	5.02e-1	67/77 (87.01%)	ITGA4;TLR4;ITGAM;...
Pertussis	1.28	5.12e-1	64/76 (84.21%)	TLR4;CASP3;C1S;...
Pyruvate metabolism	1.27	5.28e-1	41/47 (87.23%)	DLD;ACAT1;ACAT2;...
Endometrial cancer	1.27	5.16e-1	56/58 (96.55%)	KRAS;GADD45B;LEF1;...
Malaria	-1.31	4.47e-1	44/50 (88%)	IL18;IL10;TGFB1;...
GABAergic synapse	-1.32	4.22e-1	76/89 (85.39%)	ADCY9;GAD1;ABAT;...
FoxO signaling pathway	-1.33	4.16e-1	118/131 (90.08%)	HOMER2;FOXO3;AKT1;...
Legionellosis	-1.33	4.30e-1	51/57 (89.47%)	SAR1A;NAIP;EEF1A2;...
Vascular smooth muscle contraction	-1.34	4.17e-1	113/133 (84.96%)	EDN1;ACTG2;ACTA2;...
Glutamatergic synapse	-1.34	4.25e-1	97/114 (85.09%)	GRM2;HOMER2;PLA2G4A;...
cAMP signaling pathway	-1.34	4.35e-1	188/216 (87.04%)	RELA;SLC9A1;FXYD1;...
Pathways of neurodegeneration	-1.35	4.27e-1	354/475 (74.53%)	STX1A;CASP9;NDUFS4;...
Arginine biosynthesis	-1.35	4.46e-1	17/22 (77.27%)	GLUL;ARG2;ASS1
p53 signaling pathway	-1.38	4.01e-1	63/73 (86.3%)	BID;IGF1;CD82;...
Insulin secretion	-1.38	4.19e-1	75/86 (87.21%)	KCNMA1;KCNMB4;RYR2;...
mTOR signaling pathway	-1.38	4.26e-1	114/154 (74.03%)	TSC1;GSK3B;FZD10;...
Measles	-1.38	4.42e-1	133/139 (95.68%)	CCNE1;TLR7;IL1A;...
Inflammatory mediator regulation of TRP channels	-1.41	4.02e-1	82/98 (83.67%)	ADCY2;PLA2G4C;IL1R1;...
Alanine, aspartate and glutamate metabolism	-1.43	3.70e-1	27/37 (72.97%)	ASNS;PPAT;CAD;...
Influenza A	-1.43	3.92e-1	156/172 (90.7%)	CCL5;IL18;TLR7;...
Cortisol synthesis and secretion	-1.48	3.09e-1	58/65 (89.23%)	CYP11B1;HSD3B2;LDLR;...
Renin-angiotensin system	-1.49	2.94e-1	20/23 (86.96%)	AGT;KLK2;ACE2;...
Rheumatoid arthritis	-1.49	3.06e-1	78/93 (83.87%)	CCL5;IL18;CSF1;...
Alzheimer disease	-1.50	3.22e-1	279/369 (75.61%)	CASP9;NDUFS4;ULK1;...
Ribosome	-1.51	3.37e-1	113/158 (71.52%)	MRPS11;MRPL13;RPL32;...
Spinocerebellar ataxia	-1.52	3.48e-1	128/143 (89.51%)	ULK1;ATG2B;PSMD4;...
African trypanosomiasis	-1.60	2.02e-1	32/37 (86.49%)	IL18;IL10;IDO1;...
Diabetic cardiomyopathy	-1.61	1.99e-1	162/203 (79.8%)	NDUFS7;INSR;MAPK13;...
Porphyrin and chlorophyll metabolism	-1.66	1.52e-1	23/43 (53.49%)	COX10;UGT2B4;UGT2A3;...
Non-alcoholic fatty liver disease	-1.68	1.59e-1	126/155 (81.29%)	NDUFS4;NDUFA4;MAPK10;...
Protein digestion and absorption	-1.68	1.98e-1	78/103 (75.73%)	COL8A2;XPNPEP2;COL14A1;...
Parkinson disease	-1.70	2.14e-1	176/249 (70.68%)	CASP9;NDUFS4;NDUFA4;...
Vitamin digestion and absorption	-1.83	7.50e-2	17/24 (70.83%)	APOA4;LMBRD1;BTD;...
Prion disease	-1.87	9.65e-2	209/273 (76.56%)	KLC1;IL1A;BAD;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	15uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.04uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H